Our Pipeline

About PRAME

PRAME is a target expressed in more than 50 cancers. Immatics is the global leader in precision targeting of PRAME and has the broadest PRAME franchise with the most PRAME indications and modalities.

The Immatics PRAME franchise currently includes three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy.

Pipeline

Preclinical

Phase 1a

Dose escalation

Phase 1b

Dose expansion

Phase 2

Phase 3

PRAME

PRODUCT CANDICATE: Anzu-cel (IMA203)

SUPRAME

Modality: Cell therapy

Indication: 2L melanoma, patients with unresectable or metastatic melanoma who have received at least 1 prior immune checkpoint inhibitor

Target: PRAME

PRODUCT CANDICATE: Anzu-cel (IMA203)

Modality: Cell therapy

Indication: Uveal melanoma

Target: PRAME

Anzu-cel (IMA203) + mRNA-4203

Modality: Cell therapy

Indication: Solid cancers

Target: PRAME

IMA203CD8

Modality: Cell therapy

Indication: Gynecologic cancers, other solid cancers

Target: PRAME

IMA402

Modality: Bispecific

Indication: Melanoma, gynecologic cancers and others

Target: PRAME

IMA402 + ICI

Modality: Bispecific

Indication: Melanoma, gynecologic cancers and others

Target: PRAME

IMA402 + IMA401

Modality: Bispecific

Indication: sqNSCLC

Target: PRAME, MAGEA4/8

IMA401 with or without checkpoint inhibitor (pembrolizumab)

Modality: Bispecific

Indication: HNSCC, sqNSCLC and others

Target: MAGEA4/8

Undisclosed

Modality: Bispecific

Indication: Undisclosed

Target: other

^{Anzu-cel: anzutresgene autolecel (formerly IMA203)}
^{HNSCC: head and neck squamous cell carcinoma}
^{sqNSCLC: squamous non-small-cell lung cancer}

The PRAME franchise

Product candidates

Therapeutic modalities

Combination therapies

Clinical trials

Immatics is evaluating its targeted PRAME cell therapies and bispecific product candidates and actively enrolling patients in ongoing clinical trials.